| Source: CGL-Driver Genes |
| Type: Oncogene |
| DNMT1 overexpression in various cancer types. DNA (cytosine-5-)-methyltransferase 1, commonly referred to as DNMT1, is an enzyme that plays a crucial role in the maintenance of DNA methylation patterns. Increased DNMT1 activity can promote tumorigenesis by facilitating the accumulation of methylation changes that drive cancer progression. Is frequently overexpressed in a variety of cancers, including breast, colorectal, lung, prostate, and hematological malignancies. This overexpression is often associated with hypermethylation of tumor suppressor genes, leading to their silencing and contributing to tumorigenesis. |
| Colon cancer can start anywhere in the colon, (5 feet long) and absorbs water from stool. Rectal cancer starts in the rectum, which is the last 12 centimeters. |
| 2712- | BBR, | Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs) |
| - | in-vitro, | Colon, | HT29 | - | in-vivo, | NA, | NA |
| 3236- | EGCG, | Buty, | Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate |
| - | in-vitro, | Colon, | RKO | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | HT29 |
| 2915- | LT, | Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | SNU-407 | - | in-vitro, | Nor, | FHC |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:31 Cells:% prod#:% Target#:85 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid